Evercore ISI Group analyst Thomas Gallagher maintains Lincoln National (NYSE:LNC) with a In-Line and lowers the price target from $78 to $66.
Ligand Pharmaceuticals Licensor Of Sermonix Pharmaceuticals Shares Details Of Durable Complete Clinical Response In A Metastatic ER+/HER2- Breast Cancer Patient With An ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Ba…
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah
